Structure Therapeutics (NASDAQ: GPCR) has received an upgrade from Wall Street Zen, moving from a “sell” rating to a “hold” rating as reported on Saturday. This shift reflects a more cautious optimism among analysts regarding the company’s potential in the biopharmaceutical sector.
In addition to Wall Street Zen’s assessment, several other financial institutions have weighed in on Structure Therapeutics. HC Wainwright reaffirmed a “buy” rating, establishing a price target of $60.00 on November 28. Morgan Stanley raised its price target from $120.00 to $125.00 and rated the stock as “overweight.” Meanwhile, Stifel Nicolaus increased its price objective from $50.00 to $90.00, also giving the company a “buy” rating in a report released on December 8.
Conversely, Zacks Research downgraded Structure Therapeutics from a “hold” rating to a “strong sell” rating on October 17, showing the mixed sentiment among analysts. Lifesci Capital took a more positive stance, upgrading the stock to a “strong buy” on September 8. Currently, one research analyst has designated the stock with a “strong buy” rating, while eleven have rated it as a “buy” and two have issued a “sell” rating. According to data from MarketBeat, Structure Therapeutics has an average rating of “Moderate Buy” and an average target price of $95.78.
Financial Performance and Future Expectations
Structure Therapeutics reported its quarterly earnings on November 6, revealing a loss of ($0.37) per share, which fell short of the consensus estimate of ($0.36) by ($0.01). Analysts forecast that the company will post earnings of ($0.82) per share for the current fiscal year, reflecting the challenges it faces in achieving profitability.
Institutional Investor Activity
Recent changes in institutional investment have also impacted Structure Therapeutics. In the second quarter, the State of Wyoming acquired a new stake valued at approximately $28,000. EverSource Wealth Advisors LLC significantly increased its stake by 530.0% during the third quarter, now owning 1,071 shares worth around $30,000 after purchasing an additional 901 shares.
National Bank of Canada FI raised its position in the company by 1,448.2% in the first quarter, owning 2,957 shares now valued at $51,000. Additionally, Assetmark Inc. boosted its stake by 39.9% in the second quarter, now holding 2,877 shares worth $60,000. PNC Financial Services Group Inc. also increased its position by 29.1%, now owning 4,415 shares valued at $92,000. Notably, approximately 91.78% of Structure Therapeutics stock is currently owned by hedge funds and other institutional investors.
About Structure Therapeutics
Structure Therapeutics Inc. is a clinical-stage global biopharmaceutical company focused on developing innovative oral therapeutics to address a variety of chronic diseases with significant unmet medical needs. The company’s lead candidate, GSBR-1290, is an oral small molecule agonist targeting the glucagon-like peptide-1 receptor, a validated target for medications addressing type-2 diabetes and obesity.
The evolving landscape of analyst ratings and institutional investment reflects a complex view of Structure Therapeutics’ future potential. As the company continues navigating its clinical developments, the market’s response will be closely monitored.
